LID17 Dec 2012 07:50
Trading update
LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to announce that, as outlined in the interim results and recent equity funding, it has now acquired the existing LiDCOrapid customer base from Covidien, its previous US distribution partner. Consequently LiDCO's own direct sales organization, headquartered near Chicago, has now taken full responsibility for the sale and distribution of all LiDCOrapid products in the US.
The Board believes that, after an initial integration and switch-over period, the associated revenues from this customer base will enhance the profitability of the Company. The Company is continuing discussions with a number of potential partners in the US market and will update shareholders in due course.
The Company recently demonstrated the LiDCOrapid v2 at the American Society of Anesthesia (ASA) annual meeting in Washington, US and the European Society of Intensive Care (ESICM) meeting in Lisbon, Portugal. The responses from practitioners at both conferences were very encouraging and the Company expects this new product to drive increased disposable use in 2013 and beyond. This is the first monitor to be designed specifically for multi-parameter monitoring, of depth of anesthesia and fluid management, and set to benefit from two recent NICE recommendations for use in high risk surgery patients.